GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Trofinetide - DAYBUE / DAYBUE STIX

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

DAYBUE / DAYBUE STIX / trofinetide

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Adult and pediatric eGFR units differ within this label

The same printed numeric bands use absolute units in adults and indexed units in children. Packet restrictions also matter for reduced amounts.

Before applying: Do not substitute one unit convention or use partial powder packets.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

DailyMed / DAYBUE and DAYBUE STIX exact label

Product / population
Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.
Renal measure
Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2

Selected sections only. Source mirror and underlying label are not independent confirmations.

Renal dosing, restrictions and evidence limits

Mild impairment (eGFR 60-89): no adjustment. Moderate impairment (30-59) uses these twice-daily amounts: 9 to <12 kg, 2500 mg; 12 to <20 kg, 3000 mg; 20 to <35 kg, 4000 mg; 35 to <50 kg, 5000 mg; 50 kg or more, 6000 mg. Severe impairment below 30: use is not recommended.

The table uses eGFR in mL/min for adults and mL/min/1.73 m2 for pediatric patients. For doses below 5000 mg, the label recommends DAYBUE solution; do not use partial STIX packets. Severe diarrhea, dehydration, weight loss or persistent vomiting may require interruption, reduction or discontinuation. These are selected renal instructions, not the complete weight-based prescribing information.

Source revision: 3/2026 | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e6f2d9-21f6-466f-9def-826c6a4b8257

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

DailyMed / DAYBUE and DAYBUE STIX exact label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.

Renal method: Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - DAYBUE

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.

Renal method: Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Adult and pediatric eGFR units differ within this label

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measure and formulation

Adult and pediatric eGFR units differ within this label

The same printed numeric bands use absolute units in adults and indexed units in children. Packet restrictions also matter for reduced amounts.

How to use this: Do not substitute one unit convention or use partial powder packets.

GlobalRPh RX List - DAYBUEDailyMed / DAYBUE and DAYBUE STIX exact label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDailyMed / DAYBUE and DAYBUE STIX exact labelGlobalRPh RX List - DAYBUE
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/daybue-drug/

Exact product and population

Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.

RDM54-SCOPE-trofinetide-daybue · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

DailyMed / DAYBUE and DAYBUE STIX exact label

Open original reference

Open / share this exact local source

DailyMed / Acadia Pharmaceuticals Inc. · Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.

Renal method: Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Source date: 3/2026
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Mild impairment (eGFR 60-89): no adjustment. Moderate impairment (30-59) uses these twice-daily amounts: 9 to <12 kg, 2500 mg; 12 to <20 kg, 3000 mg; 20 to <35 kg, 4000 mg; 35 to <50 kg, 5000 mg; 50 kg or more, 6000 mg. Severe impairment below 30: use is not recommended.

The table uses eGFR in mL/min for adults and mL/min/1.73 m2 for pediatric patients. For doses below 5000 mg, the label recommends DAYBUE solution; do not use partial STIX packets. Severe diarrhea, dehydration, weight loss or persistent vomiting may require interruption, reduction or discontinuation. These are selected renal instructions, not the complete weight-based prescribing information.

RDM54-official-trofinetide-daybue-b33fe11626-C1 · Source locator: Sections 2.3-2.6, renal Table 4; 5.1-5.3; 8.6

Source-specific limits

Selected sections only. Source mirror and underlying label are not independent confirmations.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e6f2d9-21f6-466f-9def-826c6a4b8257
Retrieved
2026-09-09
Exact label title
DAYBUE - trofinetide solution; DAYBUE STIX - trofinetide for solution
DailyMed Set ID
67e6f2d9-21f6-466f-9def-826c6a4b8257
Labeler
Acadia Pharmaceuticals Inc.
DailyMed page updated
2026-08-18
Label revision
3/2026
Renal-function method
Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Source date/version
3/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ded56c793cc6ba76c576331ba27db665925493c524793550cb18069463e46d6b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - DAYBUE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Trofinetide DAYBUE 200 mg/mL oral solution and DAYBUE STIX oral powder for Rett syndrome in patients aged 2 years and older. The selected dosing table begins at 9 kg.

Renal method: Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Mild impairment (eGFR 60-89): no adjustment. Moderate impairment (30-59) uses these twice-daily amounts: 9 to <12 kg, 2500 mg; 12 to <20 kg, 3000 mg; 20 to <35 kg, 4000 mg; 35 to <50 kg, 5000 mg; 50 kg or more, 6000 mg. Severe impairment below 30: use is not recommended.

The table uses eGFR in mL/min for adults and mL/min/1.73 m2 for pediatric patients. For doses below 5000 mg, the label recommends DAYBUE solution; do not use partial STIX packets. Severe diarrhea, dehydration, weight loss or persistent vomiting may require interruption, reduction or discontinuation. These are selected renal instructions, not the complete weight-based prescribing information.

RDM54-rxlist-trofinetide-daybue-c0e2f47889-C1 · Source locator: Dosage and Administration; Renal Impairment; selected Warnings and Precautions

Source-specific limits

Selected sections only. Source mirror and underlying label are not independent confirmations.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/daybue-drug/
Retrieved
2026-09-09
Renal-function method
Adult eGFR, mL/min; pediatric eGFR, mL/min/1.73 m2
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ded56c793cc6ba76c576331ba27db665925493c524793550cb18069463e46d6b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/daybue-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
20c7232a7c24b6f74e976bf0c51f4fc9aea1d4b0f3c64ca25c572fa82df81c7f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report